Nadda leads Integrity Pledge Ceremony at Ministry of Health and Family Welfare (See 'Corp Brief') RM calls for 'Aatmanirbharta 2.0', next leap in defence self-reliance, at SWAVLAMBAN 2026 (See 'Corp Brief') IBC - Admission u/s 7 IBC requires summary finding of debt & default above statutory threshold, and not exact reconciliation or forensic reconciliation of accounts: SC (See 'Legal Desk') MoRTH to organise 'Transport Mela' under PARIVARTAN Scheme in Delhi-NCR (See 'Corp Brief') NCB launches 'Operation Trident', with 38 teams striking 38 locations (See 'Corp Brief') NIFTEM-K hosts India's First AI × Food Tech Hackathon, 'Hack the Fork' (See 'Corp Brief') Misc - Administrator could neither assume RBI's write-down power at point of non-viability nor exercise it after reconstruction scheme took effect: SC (See 'Legal Desk') GeM promotes 'The AABHAR Collection' to showcase India's Cultural Heritage (See 'Corp Brief') National Conclave 2026: Technical sessions outline reforms for future-ready cities (See 'Corp Brief') PM's appeal has given a new identity to Khadi: KVIC Chairman (See 'Corp Brief') SARFAESI - Secured creditor stepping into shoes of borrower/lessee cannot claim rights superior to those of original lessee: HC (See 'Legal Desk') Three-day event 'India Chem-2026' concludes in Mumbai (See 'Corp Brief') Agricultural Biological Resources generate ABS Benefits for Biodiversity (See 'Corp Brief') BHASHINI Division showcases Multilingual AI Solutions for Accessible Research at IIT Delhi (See 'Corp Brief') Capital Market - Sec 12A of Commercial Courts Act is mandatory and strict condition precedent for maintaining commercial suit where no urgent interim relief is contemplated: HC (See 'Legal Desk') Fisheries Investors & Exporters Conclave 2026 to boost Investment and Exports from Inland Fisheries (See 'Corp Brief') India's First Maritime NBFC SMFCL scales up with Rs 5,107 Crs disbursed (See 'Corp Brief') India advances Agrivoltaics Cooperation for Global South (See 'Corp Brief') RTI - Information regarding public orders & ongoing court proceedings is already accessible in public domain - falls outside disclosure obligations of public authority under statute: SEBI (See 'Legal Desk') An unsuccessful 'success fee' litigation (See CORP EINSICHT)

Print

NPPA monitors prices of scheduled & non-scheduled medicines

Published: Jul 30, 2024

By TIOLCorplaws News Service

NEW DELHI, JULY 30, 2024: AS per the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule-I are defined under Para 2(1)(v) of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013. 

As per the extant provisions of DPCO, 2013, the ceiling prices of scheduled medicines are revised annually on the basis of Wholesale Price Index (WPI) (all commodities) for preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year and is notified by the Government on the 1st day of April every year. The details of price fixed by NPPA are available at NPPA's website i.e. nppaindia.nic.in.  In case of non-scheduled formulation (branded or generic), as per para 20 of DPCO, 2013, no manufacturers can increase Maximum Retail Price (MRP) by more than 10% of MRP during preceding 12 months.  The maximum permissible increase in prices, as per the provisions of DPCO, 2013 for scheduled and non-scheduled drugs may or may not be availed by their respective manufacturers based on commercial considerations and market dynamics.

Under the Drugs and Cosmetics Act, 1945 and Rules thereunder, manufacturers of drugs are required to comply with conditions of manufacturing licence and the requirements of Good Manufacturing Practices (GMP).  As per the Drugs Rules, 1945, the manufacturing, testing, labeling, packaging, storage and distribution are required to be carried out in compliance with the conditions of license including the Good manufacturing practices (GMP) prescribed under the Schedule M of the Drugs Rules, 1945. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013.  Action is taken against companies, found selling formulations at prices higher than the permissible price, and the overcharged amount is recovered from the company as per the relevant provisions of the DPCO, 2013. During the financial year 2023-24, Rs. 72.73 crore was recovered from the defaulting companies.

This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Rajya Sabha in reply to a question today.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.